Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EBITDA (2016 - 2025)

Vistagen Therapeutics' EBITDA history spans 13 years, with the latest figure at -$18.9 million for Q4 2025.

  • For Q4 2025, EBITDA fell 34.04% year-over-year to -$18.9 million; the TTM value through Dec 2025 reached -$67.0 million, down 41.76%, while the annual FY2025 figure was -$51.4 million, 75.1% down from the prior year.
  • EBITDA for Q4 2025 was -$18.9 million at Vistagen Therapeutics, up from -$19.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$6.2 million in Q1 2021 and bottomed at -$19.4 million in Q3 2025.
  • The 4-year median for EBITDA is -$10.7 million (2024), against an average of -$11.4 million.
  • The largest annual shift saw EBITDA crashed 288.59% in 2021 before it plummeted 34.04% in 2025.
  • A 4-year view of EBITDA shows it stood at -$10.5 million in 2021, then soared by 39.75% to -$6.4 million in 2023, then plummeted by 122.05% to -$14.1 million in 2024, then crashed by 34.04% to -$18.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EBITDA are -$18.9 million (Q4 2025), -$19.4 million (Q3 2025), and -$15.1 million (Q2 2025).